Skip to main content
Clinical Trials/NCT01598181
NCT01598181
Completed
Not Applicable

Transcranial Direct Current Stimulation (tDCS) as Treatment Method for Pain in Fibromyalgia

University Hospital of North Norway1 site in 1 country70 target enrollmentDecember 2011
ConditionsFibromyalgia

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Fibromyalgia
Sponsor
University Hospital of North Norway
Enrollment
70
Locations
1
Primary Endpoint
Perceived pain
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

The purpose of this study is to investigate Transcranial Direct Current Stimulation as treatment method for pain in fibromyalgia.

Detailed Description

Fibromyalgia (FIM) is a chronic pain condition with high prevalence. Studies involving neuroimaging techniques have identified functional differences in cerebral pain processing in patients with FIM, as compared to healthy controls. This may support that FIM do have a functional CNS component. Transcranial Direct Current Stimulation (tDCS) is a non-invasive and safe method for inducing changes in cortical excitability. Previous studies showed that anodal stimulation of M1 may change pain perception, possibly by modulating functional anomalies in the FIM brain. The present study has two main goals: 1. To investigate if tDCS may provide FIM patients with symptom relief due to reduction of pain. 2. To investigate tDCS induced functional changes in the brain by using fMRI.

Registry
clinicaltrials.gov
Start Date
December 2011
End Date
October 2013
Last Updated
9 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Sponsor
University Hospital of North Norway
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Fibromyalgia (ACR-90 criteria, M79.7 ICD10)
  • Mean VAS \> 4 daily 2 weeks prior to study).

Exclusion Criteria

  • Severe mental disease
  • CNS disease
  • Mental retardation
  • Age \< 18

Outcomes

Primary Outcomes

Perceived pain

Time Frame: Change in VAS from baseline up to 49 days.

Pain (intensity and unpleasentness) measured with Visual Analog Scale. Repported at 3 points daily (0900hrs, 1500hrs, 2100hrs) using Short Message System (SMS) 14 days pre-treatment (baseline), during treatment 5 days, and 30 days post-treatment. Measure effect of active\\sham tDCS on pain. 2 levels of group (active tDCS\\ sham tDCS, 7 repeated measures: pre-treatment day 1, 2 ,3, 4, 5 - post) SMS messages contain 4 questions, mesauring pain intensity / pain unpleasentness (primary outcome), and stress / activation (secondary outcome).

Secondary Outcomes

  • Cerebral pain processing(Change from baseline to post treatment. 7 days.)
  • Rating scales (HADS, SCL90, SF36, FIQ)(Change from baseline to post treatment. 30 days post treatment. Up to 65 days.)
  • Perceived pain, natural history(Baseline compared to post-treatment. Up to 65 days)
  • Perceived stress and activation(Change in VAS from baseline to during treatment and after treatment. Up to 49 days.)
  • Perceived stress and activation, natural history(Baseline compared to post-treatment. Up to 65 days)

Study Sites (1)

Loading locations...

Similar Trials